ENTREGA

(ENT101)

TRIAL PHASE
Product Candidate
PureTech Ownership
Initial Indications
Preclinical
Phase 1
Phase 2
Phase 3
ENT-100
72.9% (Entrega)
Metabolic Disorders

Initial Indication(s):

Metabolic disorders

Patient Population:

Collaborators:

MIT  Lilly

Key Differentiation:

Designed to enable oral delivery of biologics, vaccines, and forms of medication that are not efficient in reaching the bloodstream when taken orally



ENT-100
Metabolic Disorders
72.9% (Entrega)
Preclinical

Initial Indication(s):

Metabolic disorders

Patient Population:

Collaborators:

MIT  Lilly

Key Differentiation:

Designed to enable oral delivery of biologics, vaccines, and forms of medication that are not efficient in reaching the bloodstream when taken orally



Enabling the delivery of biologics via the gut epithelium to local and distal sites of the body.

Founded by PureTech, Entrega is focused on the oral delivery of biologics, vaccines, and other drugs that are otherwise not efficiently absorbed when taken orally. The vast majority of biologic drugs (including peptides, proteins, and other macromolecules) are currently administered by injection, which can present challenges for healthcare delivery and compliance with treatment regimes. Oral administration thus represents an ideal administration approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.

Our technology platform is an innovative approach to oral delivery which uses a proprietary, customizable hydrogel dosage form to control local fluid microenvironments in the GI tract to both enhance absorption and reduce the variability of drug exposure. To validate our technology, we generated proof-of-concept data demonstrating delivery of therapeutic peptides into the bloodstream of large animals.

  • Patient Need & Market Potential
    • The total global biologics market could be close to $400 billion by 2025.
    • Injectable formulations can be limited in their therapeutic potential as a result of issues with compliance, and they can be difficult and potentially unsafe to deliver to patients.
  • Our Approach to Solving the Problem
    • The Entrega platform is designed to enable oral delivery of biologics, vaccines and other forms of medication that are not efficient in reaching the bloodstream when taken orally.
  • Intellectual Property
    • Entrega has broad intellectual property coverage worldwide, including nineteen (19) patent applications in six (6) families of patent filings.
    • Entrega’s patent portfolio covers oral drug devices, drug formulations, compositions of matter, methods of use, and methods of making hydrogel dosage forms for delivery of active agents.
  • Team
    • The Entrega team is comprised of experts in drug formulation and drug delivery engineering.
    • Key advisors include Dr Robert Langer (PureTech and MIT), Dr Colin Gardner (previously TransForm Pharmaceuticals, Johnson & Johnson, and Merck), Dr Rodney Pearlman (previously Nuon Therapeutics, Saegis Pharmaceuticals, and Genentech), Dr Samir Mitragotri (Wyss Institute at Harvard University, previously UC Santa Barbara), Mr Rob Armstrong (Boston Pharmaceuticals and previously Eli Lilly), and Mr Howie Rosen (previously ALZA Corporation)
  • Collaborations
    • Entrega received $5 million in equity and research funding from Eli Lilly to investigate the application of its peptide delivery technology to certain Lilly therapeutic candidates.
  • Milestones Achieved
    • Entrega has generated proof-of-concept data demonstrating successful delivery of therapeutic peptides into the bloodstream of large animals.

Entrega’s technology platform is an innovative approach to oral delivery which uses a proprietary, customizable hydrogel dosage form to control local fluid microenvironments in the GI tract to both enhance absorption and reduce the variability of drug exposure. To validate its technology, Entrega generated proof-of-concept data demonstrating delivery of therapeutic peptides into the bloodstream of large animals.